The Challenge of Thromboprophylaxis in Cancer Patients—Balancing the Thrombotic and Bleeding Risks

References
1 Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res 2016; 118 (09) 1340-1347
2 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
3 Tafur AJ, Caprini JA, Cote L. , et al; RIETE Investigators. Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis. Thromb Haemost 2017; 117 (06) 1192-1198
4 Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost 2018; 118 (02) 251-265
5 Bauersachs R, Lee AYY, Kamphuisen PW. , et al; CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH study. Thromb Haemost 2018; 118 (05) 914-921
6 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
7 Kraaijpoel N, van Es N, Bleker SM. , et al. Clinical impact and course of anticoagulant-related major bleeding in cancer patients. Thromb Haemost 2018; 118 (01) 174-181
8 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
9 Khorana AA, Weitz JI. Treatment challenges in venous thromboembolism: an appraisal of rivaroxaban studies. Thromb Haemost 2018; 118 (S 01): S23-S33
10 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
11 Schulman S, Shrum J, Majeed A. Management of bleeding complications in patients with cancer on DOACs. Thromb Res 2016; 140 (Suppl. 01) S142-S147
12 Martinez BK, Sheth J, Patel N, Baker WL, Coleman CI. Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis. Pharmacotherapy 2018; 38 (06) 610-618
13 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
14 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
15 Bleker SM, Brekelmans MPA, Eerenberg ES. , et al. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost 2017; 117 (10) 1944-1951
16 Kraaijpoel N, Di Nisio M, Mulder FI. , et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer study. Thromb Haemost 2018; 118 (08) 1439-1449
17 Lyman GH, Bohlke K, Khorana AA. , et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol 2015; 33 (06) 654-656
18 Mandalà M, Falanga A, Roila F, Group EGW. ; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92